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Abstract
Background:  We report longitudinal changes in the metabolic syndrome (MetS) in 2,458
participants from 480 families in the Family Heart Study. Participants were examined between
1994–96 (FHS-T1) and 2002–03 (FHS-T2), about 7.4 years apart. Additionally, the impact of
medication on estimates of MetS prevalence, and associations of MetS with prevalent coronary
heart disease (CHD) and type 2 diabetes (T2D) were studied.
Methods: Three definitions for MetS prevalence were considered. One represented the original
(o) National Cholesterol Education Program (NCEP) MetS criteria. Two others considered the
confounding of medications effects, respectively (m) lipid medications constituted a categorical
diagnostic criterion for lipids variables, and (c) lipids and blood pressure variables were corrected
with average clinical trials medications effects. Logistic regression of MetS on CHD and T2D, as
well as the trend analysis of MetS by age, were performed.
Results: MetS increased from 17.1% in FHS-T1(o) to 28.8% in FHS-T2(o); from 19.7% in FHS-
T1(m) to 42.5% in FHS-T2(m); and from 18.4% in FHS-T1(c) to 33.6% in FHS-T2(c). While we
observed adverse changes in all risk factors, the greatest increase was for waist circumference
(25%). The percentages of MetS were about 2 to almost 3 times higher in ages 50 years and older
than in younger ages. The odds of having prevalent CHD were about 2.5 times higher in the
subjects classified with MetS than without.
Conclusion: MetS percentages increased noticeably longitudinally and cross-sectionally with older
age. These conclusions were reached with and without considering medication use, but correcting
risk factors for medications use affects the MetS prevalence estimates. As found in other studies,
MetS was associated with increased odds for prevalent CHD.
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Background
The metabolic syndrome (MetS) is a combination of
interconnected risk factors for obesity, insulin resistance
and glucose intolerance, dyslipidemia, and hypertension.
The Adult Treatment Panel III of the National Cholesterol
Education Program (NCEP) defined a group of five clini-
cal criteria for effective classification of MetS (see Meth-
ods) [1]. An individual that meets three or more of these
criteria yields a clinical diagnosis of MetS.
Based on the NCEP classification, it is reported, that a rap-
idly growing epidemic of metabolic syndrome is taking
place in the United States [2-4]. For example, Ford and
Giles reported that about 24% of US adults (n = 8,608)
from 20–70 years of age from the Third National Health
and Nutrition Examination Survey (1988–1994), a cross-
sectional health survey of a nationally representative sam-
ple of the US civilian population, were affected by MetS
[2]. Meigs, summarizing data for the epidemiology of
MetS and diabetes, stated that more than 8% of the US
population from 20–74 years of age were affected by dia-
betes mellitus, which is often associated with MetS [3].
The prevalence of MetS varies with age and was 6.7% in
subjects 20–29 years old and about 40% in those aged 60
years or more [3]. In a study (n = 3,510) of the US popu-
lation, the prevalence of MetS was about 44% in partici-
pants 50 years and older [4].
MetS is of special interest because it represents a complex
disorder expressed by interrelated risk factors with
unknown genetic and not well known environmental
influences. Previous familial studies have shown that
MetS has an important heritable component [5-8]. While
the genetic aspects of MetS are quite important, several
studies have revealed that lifestyle modifications and/or
medication use reduce the prevalence of MetS [1,9].
One of the main features of MetS is an increased risk of
CHD and Type 2 diabetes (TD2) [10-12]. Alexander et al.
reported that participants who had MetS but not diabetes
had a 13.9% prevalence of CHD, whereas those with MetS
and diabetes had a 19.2% prevalence of CHD [4]. Only a
few studies have documented longitudinal effects of MetS,
in its association with CHD and T2D [13-15]. We studied
the same sampled population in the Family Heart Study
(FHS) – Time 1 (FHS-T1) and FHS – Time 2 (FHS-T2),
which represent two clinical visits with a mean age inter-
val of about 7.4 years. The main purpose of our study was
to assess the longitudinal trends of MetS, its association
with age, prevalent CHD and T2D, and the impact of
medication on the prevalence estimates of MetS.
Sampled populations and methods
Participants
The sampled population is part of the multi-center FHS
supported by the National Heart, Lung, and Blood Insti-
tute. It is important to mention that the original FHS
white familial sample was separated into two large
groups, one random and one non-random, based on the
participants' recruitment criteria for CHD and their famil-
ial risk for CHD. Details are provided elsewhere [[16], and
[10-12]]. There were originally 5,718 participants in the
FHS-1 (1994–96), but only large families were re-exam-
ined (2002–03). In our study, the FHS-T1 and FHS-T2
samples embodied the same 2,458 participants, from 480
families with a maximum of up to 16 members, with at
least one measurement on the 5 MetS risk factors analyzed
at both clinical visits. For a specific trait measured, if a
subject had only FHS-T1 measured and FHS-T2 was miss-
ing, or vice versa, that measure was set to missing. Blood
pressure (BP) and glucose (GLUC) variables were handled
with special care. If systolic (SBP) and diastolic blood
pressure (DBP) were missing in FHS-T1, the SBP and DBP
in FHS-T2 were set to missing. Also, the anti-hypertensive
medication use variable was set to missing. Similarly, if
GLUC of FHS-T1 was missing, GLUC of FHS-T2 was set to
missing (vice versa for Time 2 to Time 1), as well as the
diabetes state and diabetes medication use variables. Our
goal was to restrict the data to individuals with measure-
ments at both time points for each risk factor. Such a sam-
ple, with two time clinical visits and a mean age difference
of about 7.4 years, was the focus of our longitudinal com-
parisons.
NCEP metabolic syndrome definition
The percentages of MetS were identified by applying the
NCEP ATP III metabolic syndrome criteria (Table 1) [1].
An individual was classified as having MetS if they had a
combination of any three or more of the following risk
factors beyond their thresholds: waist circumference
(WAIST) > 102 cm in men and > 88 cm in women; triglyc-
eride (TG) levels ≥ 150 mg/dl; high-density lipoprotein
cholesterol (HDLC) levels < 40 mg/dl in men and < 50
mg/dl in women; SBP OR DBP ≥ 130/85 mm Hg OR use
of anti-hypertensive medications; and GLUC ≥ 110 mg/dl
OR use of anti-diabetic medications. We label this origi-
nal MetS definition as (o). The second method, labeled
(m), considered medication use for TG and HDLC as a
categorical effect and anyone on lipid lowering drugs was
classified as positive for the NCEP lipid threshold (Table
1). This second method (m) is similar to the recent criteria
proposed by the Scientific Statement of AHA/NHLBI for
diagnosing and managing MetS, with a difference that
they defined the threshold of fasting glucose to be 100
mg/dl [17]. To increase the precision of the MetS preva-
lence estimation, we also considered a third method
labeled (c), where the original measurements of SBP,Nutrition & Metabolism 2006, 3:41 http://www.nutritionandmetabolism.com/content/3/1/41
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DBP, TG, and HDLC were corrected with the average effect
observed in clinical trials (Table 1) [[18], and unpub-
lished data]. For anti-hypertensive medication(s), the par-
ticipant's SBP and DBP were corrected by adding 14.8 and
10.5 mm Hg respectively [18]. The average effects
employed for these corrections were a summary of 137
anti-hypertensive mono-drug therapy clinical trials with a
total of 10,405 participants, including trials of 6 medica-
tion classes [18]. TG and HDLC of a participant using anti-
hyperlipidemic medication(s) were similarly corrected by
dividing respectively the measured values with by the fol-
lowing coefficients (1–15.2/100) and (1+6.1/100). The
15.2 and 6.1 represent the average percentage effects of
anti-hyperlipidemic medications on TG and HDLC,
respectively. The correction coefficients used here were
estimated from 28 clinical trials with 18,742 participants
and 2 medication classes as monodrug therapy [unpub-
lished data]. The +/- sign in front of the average percentage
effect (+6.1/-15.2) shows the effect's direction (increas-
ing/decreasing) assuming that the medication altered the
corresponding individual's risk variable.
Coronary heart disease
Prevalent CHD was based on self report and/or hospital
validation of myocardial infarction, coronary bypass sur-
gery, or coronary angioplasty. In the FHS-Time 1, CHD
events were validated with hospital records. In the FHS-
T2, the CHD events were self reported.
Type 2 diabetes
T2D was defined by a fasting GLUC ≥ 126 mg/dl or cur-
rent use of hypoglycemic medication(s) that was docu-
mented as diabetes self-reported history at the
examination in the clinic. An age of onset ≥ 40 years was
also required to diagnose T2D [19].
Anthropometric, biochemical and derived measurements
All anthropometric measurements, including weight (kg),
height (m), and waist circumference (measured at the
level of the umbilicus in cm), were taken in all recruit-
ment centers by trained technicians. Trained interviewers
obtained the protocol information based upon question-
naires about the status of hypertension, medication use,
coronary heart disease risk factors, and many more. All
measured variables or subjects' responses collected were
in accordance with FHS standard procedures. Sitting
blood pressure measurements for FHS-T1 were collected
with random zero mercury sphygmomanometers by certi-
fied technicians. Those for FHS-T2 were measured using
Dinamap 1846-SX [20]. The detectable SBP ranges were
30–245 mm Hg and for DBP were 10–210 mm Hg. In
both studies, the SBP and DBP were measured three times
after the subject was asked to sit for five minutes. The
mean of the second and third measures for systolic and
diastolic represent the derived measures used in this
study.
Venipuncture blood samples were drawn and collected at
each field center. Blood biochemistries were quantified at
the Central Biochemistry Laboratory at Fairview-Univer-
sity Medical Center in Minneapolis, MN. The variables of
fasting GLUC (where fasting time was defined as ≥ 12
hours before blood draw) measured in mg/dl, HDLC
measured in mg/dl and TG measured in mg/dl represent
some of the blood biochemical assays. Details of each
procedure regarding blood collection and blood assays
are provided elsewhere [11].
Statistical analysis
Identification of MetS groups was performed using pro-
grams written in the SAS language v. 9.1.3 for Linux OS
Table 1: Diagnostic Criteria for Metabolic Syndrome Utilized in this Study
(o) Method* (m) Method** (c) Method***
No Five NCEP criteria† Categories Categories Categories
1 Elevated WAIST > 102 cm in men
> 88 cm in women
Idem¶
Idem
Idem
Idem
2 Elevated Fasting GLUC ≥ 110 mg/dl
OR use of anti-diabetic medications‡
Idem
Idem
Idem
Idem
3E l e v a t e d  T G ≥ 150 mg/dl Idem
OR antihyperlipidemic 
treatment‡
If treated with antihyperlipidemics, the original 
TG was evaluated as TG/(1–15.2/100)‡
≥ 150 mg/dl
4 Reduced HDLC < 40 mg/dl in men
< 50 mg/dl in women
Idem
Idem
OR antihyperlipidemic 
treatment‡
If treated with antihyperlipidemics, the original 
HDLC was evaluated as HDLC/(1+6.1/100)‡
< 40 mg/dl in men
< 50 mg/dl in women
5 Elevated Blood Pressure ≥ 130 mm Hg SBP
OR ≥ 85 mm Hg DBP
OR medication treatment for hypertension‡
Idem
Idem
Idem
If treated with antihypertensives, the original 
SBP was evaluated as SBP+14.8 mm Hg‡
AND the original DBP was evaluated as 
DBP+10.5 mm Hg‡
≥ 130 mm Hg SBP
OR ≥ 85 mm Hg DBP
*Original NCEP MetS criteria; **Subjects treated with antihyperlipidemics were considered as passed the corresponding threshold criterion; 
***Average effects of many clinical trials were used to impute the original values of treated TG, HDLC, SBP, and DBP. After this correction, 
categories of MetS were applied. † Any three of the five criteria constituted a diagnosis of MetS; ‡See Methods for details; ¶Identical with the left 
column category of the same row.Nutrition & Metabolism 2006, 3:41 http://www.nutritionandmetabolism.com/content/3/1/41
Page 4 of 9
(page number not for citation purposes)
(SAS Institute, Cary, NC). Procedure FREQ and LOGISTIC
regression were carried out to analyze the associations of
MetS with CHD and T2D, and to obtain the respective
odds ratios. The Cochran-Armitage trend test was applied
in SAS to test trends of MetS in decades of age groups.
Results
The mean age difference of subjects between the FHS-T1
and FHS-T2 exams was about 7.4 years (Table 2). WAIST
increased from a mean of 96.7 cm in FHS-T1 to 99.3 cm
in FHS-T2. Similar increases were noted for GLUC and
SBP. SBP and DBP at FHS-T2 showed a notable increase,
especially after a correction for anti-hypertensive medica-
tions use. On the contrary, HDLC values decreased across
exams, as well as after corrections for anti-hyperlipidemic
medications use. The mean of TG decreased from FHS-
T1(o) to FHS-T2(o), but it increased from FHS-T1(c) to
FHS-T2(c) (Table 2).
Estimates of MetS percentages were 17.1% for FHS-T1(o)
and 28.8% for FHS-T2(o) when medication use for lipids
was not considered. The additional categorical correction
of risk factor levels for lipids medication use produced the
highest MetS percentages: 19.7% for FHS-T1(m) and
42.5% for FHS-T2(m), while the third method of correc-
tion of the lipid and blood pressure values yielded preva-
lence estimates of 18.4% and 33.6% at baseline and
follow-up. The percentage change of MetS from FHS-T1
(o), (m), and (c) to FHS-T2 (o), (m), and (c) were 11.7%,
22.8%, and 15.2% respectively. The risk factors that
exceeded the NCEP thresholds were waist (increased by
24.9%), 18.6%, 30.5%, and 21.6% for low HDLC, 17.4%,
17.4%, and 12.7% for high BP, respectively, for (o), (m),
and (c), and 7.1% for high GLUC over the period (see Fig-
ure 1). Also the percentages of participants with at least 3
(MS3), 4 (MS4) and 5 (MS5) risk factors beyond the met-
abolic syndrome NCEP thresholds at Time 2 were almost
doubled compared to Time 1. For example, in the FHS-T1
(c) the percentages were 12.2, 5.1, and 1.1, compared to
FHS-T2 19.1, 11.6, and 3 percent respectively for MS3,
MS4, and MS5. CHD events increased 4% from Time 1 to
Time 2. The odds ratios and 95% confidence intervals of
having prevalent CHD in the presence of MetS were 2.8
(2.1–3.8), 2.9 (2.2–3.9), and 2.5 (1.9–3.5), respectively,
for FHS-T1(o), FHS-T1(m), FHS-T1(c) and 2.3 (1.8–2.9),
4.7 (3.6–6.1), 2.4 (1.9–3.0), respectively, for FHS-T2(o),
FHS-T2(m), and FHS-T2(c). A 12–13 fold higher odds
were found for T2D in the presence of MetS. T2D percent-
age had increased from 4.1% in FHS-T1 to 7.3% in FHS-
T2.
Age also plays an important role in accumulating adverse
events that contribute to the MetS expression. The
Cochran-Armitage trend tests evidenced significant differ-
ences (p < 0.0001) for MetS through 5 age groups (<30,
30–<40, 40–<50, 50–<60, >70) in both FHS-T1 and FHS-
T2 (data not shown). Because there was an age shift of the
same participants between two time measurements, we
compared the prevalence of MetS ages 50 and older for
FHS-T1 with those 55 and older for FHS-T2. Such compar-
ison with an age shift of 5 years was performed with the
purpose to reduce confounding effect of age. The shift
comparison is referred to as 50/55. MetS percentages for
participants of age greater or equal to 50/55 increased
from FHS-T1 (o), (m), and (c) to FHS-T2, respectively,
from 26.1% to 43.3%, from 26.9% to 54.7%, and from
25.0% to 42.2%. Of particular interest were the ratios of
MetS percentages for participants 50/55 years or older ver-
Table 2: Participants' characteristics
Variables N Mean Std. Dev. Mean Std. Dev. Mean Std. Dev. Mean Std. Dev.
Original FHS-Time1 Original FHS-Time2 Corrected FHS-Time1* Corrected FHS-Time2
AGE 2458 50.6 13.0 58.0 13.0 - - - -
BMI 2337 27.6 5.3 29.0 5.6 - - - -
WAIST 2334 96.7 14.9 99.3 16.0 - - - -
GLUC 1877 97.1 23.1 100.0 21.4 - - - -
HDLC 2417 50.1 14.5 48.8 14.3 50.0 14.5 48.1 14.3
TG 2419 148.9 100.3 144.1 92.1 149.2 100.9 151.2 97.8
SBP 2330 116.0 17.0 121.2 20.3 118.9 20.0 126.4 23.6
DBP 2330 69.0 9.7 69.7 9.8 71.1 11.3 73.4 11.4
Ratio smokers
vs. non-smokers - 0 . 4 1 - 0 . 2 6 -----
Ratio males
vs. females - 0 . 8 2 - 0 . 8 2 -----
*The value of a trait was corrected if a participant used medication for improving the profile of lipids/of BP (see Methods)Nutrition & Metabolism 2006, 3:41 http://www.nutritionandmetabolism.com/content/3/1/41
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sus MetS percentages of participants younger than 50/55
years at each time. We expected smaller ratio values when
percentages were more similar between the two age
groups. The ratios were 2.3 in FHS-T1(o), 2.4 in FHS-
T1(m), 2.3 in FHS-T1(c) versus 1.9 in FHS-T2(o), 2.1 in
FHS-T2(m), and 1.9 in FHS-T2(c). The above results may
point to an increasing secular trend for MetS in the Time
2. These data, furthermore, were separated in familial ran-
dom and familial CHD selected subsamples (See Meth-
ods, and see Figures 2 and 3). For the familial random
selected sample, respectively for the three methods (o),
(m), and (c), the following increments (11.3, 17.9),
(14.2, 25.1), and (11.2, 16.7) in percent (paired for ages
younger than 50/55, 50/55 and older) from FHS-T1 to
FHS-T2 were identified. For the familial CHD selected
sample, in the same order as above, increments of (10.7,
16.4), (13.7, 30.2), and (10.0, 17.8) percent from FHS-T1
to FHS-T2 were documented. There were no statistical dif-
ferences in the MetS prevalence between males and
females in this white matched cohort (results not shown).
Discussion
This study shows that the percentage of MetS increased
substantially over a 7.4 year period in the NHLBI Family
Heart Study, and the major contributors to this increase
were central obesity, dyslipidemia, and hypertension.
Central adiposity (assessed here as waist circumference)
appears to be the primary risk factor driving this longitu-
dinal change in MetS prevalence (see Figure 1). Obesity
and central obesity have been linked to insulin resistance
Percentages of MetS and its risk factors in the FHS-Time 1 and FHS-Time 2 Figure 1
Percentages of MetS and its risk factors in the FHS-Time 1 and FHS-Time 2. Three analyses were applied: FHS-T1 (o)/FHS-T2 
(o) – original MetS (no medication effects on lipids were considered); FHS-T1 (m)/FHS-T2 (m) – medication effects on BP, lip-
ids, and GLUC were considered as categorical effects; FHS-T1 (c)/FHS-T2 (c) – for participants that used anti-hypertensive/
anti-hyperlipidemic medication(s), corrections of the corresponding risk factors with clinical trials medication average effects 
for BP and lipids were performed (see Methods). Footnote. MS3, MS4, MS5 are the percentages of participants with at least 3, 
4, and 5 risk factors beyond the MetS NCEP thresholds.Nutrition & Metabolism 2006, 3:41 http://www.nutritionandmetabolism.com/content/3/1/41
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and hyperinsulinemia and may be the cause of dyslipi-
demia and hypertension. It should be noted that MetS
percentages in ages 50/55 and older were almost 2–3
times higher than in the younger age groups. It can be
hypothesized that a life time accumulation of adversities
including overnutrition, a sedentary lifestyle, obesity and
dyslipidemia, changes in the hormones, untreated hyper-
tension, changes of the functioning of beta cells and other
environmental and physiological factors, may trigger a
genetic expression of MetS which becomes more promi-
nent with biological maturation [14,17]. The rapid
increase in the prevalence of obesity portends a further
increase in the prevalence of the metabolic syndrome in
the future.
The precision of defining MetS for epidemiological stud-
ies is made difficult by the fact that medication treatment
can potentially change the level of each risk factor [1,17].
Medication use was exploited by us as an index to correct
the level of the actual risk factors in an attempt to estimate
the original risk factor levels. In our opinion, most studies
of MetS consider the use of medications for changing BP
and GLUC risk factors levels as a confirmation that a par-
ticipant already achieved the NCEP threshold of the spec-
ified risk factor. Such considerations are not as common
for TG and HDLC since the efficacy of lipid lowering drug
classes differ considerably for these traits. In the FHS-T1
there were 0.98% of subjects that used cholesterol lower-
ing drugs and 19.1% that used anti-hypertensive medica-
Trends of MetS percentages per age groups in the FHS-Time 1 in a familial random sample and in a familial CHD selected sam- ple Figure 2
Trends of MetS percentages per age groups in the FHS-Time 1 in a familial random sample and in a familial CHD selected sam-
ple. Reported are the corresponding percentages of MetS by 5 years age groups, as well as percentages of ages up to 50, 50 and 
older for FHS-Time 1, for (o), (m), and (c) methods (see Methods).Nutrition & Metabolism 2006, 3:41 http://www.nutritionandmetabolism.com/content/3/1/41
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tions. In the FHS-T2 this group broadened to 24.5% that
used anti-hyperlipidemics, and to 33.5% that used anti-
hypertensive medications. To capture the importance of
the lipid lowering medication use in the MetS prevalence
estimation, we considered the use of medications for
changing BP, lipids, and GLUC risk factor levels as a cate-
gorical confirmation that a participant had reached the
NCEP threshold. Therefore the difference between MetS
percentages estimated by the (o) and (m) methods within
the same time was expected to reflect a change only about
the lipids lowering medication use. The difference in the
MetS percentages between methods was negligible at the
baseline FHS visit [FHS-T1(m) and FHS-T1(o) (0.4%)],
but larger at the follow-up visit [FHS-T2(m) and FHS-
T2(o) (7.9%). This emphasizes the fact that the expansion
of the prevalence of lipid lowering medication use can
raise the MetS prevalence estimation, and should be con-
sidered.
A third approach was performed in an attempt to impute
the original levels of treated BP/lipids MetS risk factors
(see Methods). This third method resulted in MetS per-
centages of 18.4% at baseline and 33.6% at follow-up (see
Figure 1). We believe that a correction based on the aver-
age effects of anti-hypertensives and anti-hyperlipidemics
clinical trials on risk factor levels is probably the closest in
estimating the MetS prevalence.
For the three methods applied, similar trends were
noticed when familial samples were selected random/for
CHD (See Methods and see Figures 2 and 3). When low-
ering the glucose threshold to 100 mg/dl as recom-
Trends of MetS percentages per age groups in the FHS-Time 2 in a familial random and in a familial CHD selected sample Figure 3
Trends of MetS percentages per age groups in the FHS-Time 2 in a familial random and in a familial CHD selected sample. 
Reported are the corresponding percentages of MetS by 5 years age groups, as well as percentages of ages up to 55, 55 and 
older for FHS-Time 2, for (o), (m), and (c) methods (see Methods).Nutrition & Metabolism 2006, 3:41 http://www.nutritionandmetabolism.com/content/3/1/41
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mended recently by AHA/NHLBI [17] in comparison to
110 mg/dl recommended by the NCEP MetS definition,
the MetS percentages became 22.3%, 22.7%, 21.4% in
FHS-T1, and 38.5%, 46.0%, 37.5% in FHS-T2, represent-
ing an increment of about 3% of MetS in both times for
(o), (m), and (c) methods.
It was apparent, when comparing results of FHS-T1 vs.
FHS-T2, that the presence of MetS in the sample was asso-
ciated with higher odds for prevalent CHD. The odds of
having prevalent CHD in the presence of MetS were about
2.5 times higher than in its absence in FHS-T1(c) and
FHS-T2(c). Higher presence of prevalent CHD and T2D
when participants were classified with MetS may imply
that MetS and/or its contributing risk factors are associ-
ated with the development of CHD and T2D. Similar find-
ings were reported in other publications [5,10,21-24].
Our study also has limitations. Although the MetS preva-
lence in FHS-T2 was noticeably higher than in FHS-T1, in
the FHS-T2 sample analyzed we have not accounted for
any mortality as result of CHD. Malik et al. examined the
impact of MetS on CHD and on the overall mortality in
the US adults. They reported a 2.2 hazard ratio for CHD
mortality when subjects were classified with MetS [25]. As
a result, the estimated prevalence of CHD in FHS-T2 may
be conservative. A second possible limitation was related
to the recruitment design used in the FHS-T2. Each recruit-
ment center in the study had a goal for the total number
of recruited participants and stopped recruiting when they
reached the goal. This feature of the recruitment in the
FHS-T2 had a potential for bias, especially if the selected
sample was biased toward individuals selected for CHD or
with familial history of CHD. Although this has been con-
sidered to be prevented by each center, we found that
46.6% of the sample was from the original random sam-
ple and 53.4% was from the original sample selected for
family history of CHD. A third possible limitation is
related to the equipment used to measure BP. In the FHS
study, blood pressure was measured with two different
devices (see Methods). The concern was that the change in
equipment may impact the MetS prevalence reported.
Although Rose at al [20] informed a skip problem for
Dinamap for SBP, Sturrock et al [26] have reported that
there is an agreement of sphygmomanometer and
Dinamap readings. Also, Kuo et al [27] concluded that the
averaged readings of duplicate BP measurements by
Dinamap were interchangeable with that by sphygmoma-
nometer. Thus, our method of using the average of the
second and third measurements of BP asserts that the two
time BP measurements on the same subject are compara-
ble.
Another limitation relates to medication use and MetS
definition. In the second method we classified subjects
under lipid medication as passing the threshold of MetS
for elevated TG and low HDL. This is potentially problem-
atic from a clinical point of view, because not all lipid
medications are prescribed for elevated TG or low HDL.
Often such medications are prescribed for elevated LDL.
From the experience of studying different clinical trials
(unpublished data), in this study we assumed that there
are correlated medication effects on LDL, HDL, and TG
traits. Also for each medication prescribed there are over
and under responders. By adjusting everyone on a medi-
cation, (regardless of compliance, which in our study was
not known), by an average medication efficacy or a per-
centage there is a potential to over-/under estimate the
original imputed HDL, TG, BP, and concurrently the MetS
prevalence. Therefore to overcome this limitation, (where
data are available), we recommend in similar studies for
treated risk factors, their correction per participant with
average effects of specific classes of medications matched
to specific medication labels [18].
We conclude that when estimating the MetS prevalence it
is important to account for the medications use that con-
founds MetS risk factors. To account categorically for anti-
hyperlipidemic medication use is a difficult task that can
overestimate MetS prevalence. Our study demonstrated
also that MetS is associated with a higher risk for prevalent
CHD and T2D. This finding is supported by the scientific
literature, which in addition shows that CHD mortality is
higher in individuals with MetS than without [25,28].
MetS amplifies with age and is becoming more prevalent
over time. Its prevention, by targeting specific MetS risk
factors or a combination of them, is a crucial step to inter-
rupt its epidemic.
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